Skip Navigation LinksHome > September 2002 - Volume 35 - Issue 3 > Consensus Report on Nutrition for Pediatric Patients With Cy...
Journal of Pediatric Gastroenterology & Nutrition:
Medical Position Papers

Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis

Borowitz, Drucy*; Baker, Robert D.*; Stallings, Virginia†

Free Access
Article Outline
Collapse Box

Author Information

*Children's Hospital of Buffalo, Buffalo, New York, U.S.A.; Children's Hospital of Philadelphia For the Consensus Committee, Philadelphia, Pennsylvania, U.S.A.

Address correspondence and requests for reprints to Robert D. Baker, MD, PhD, Digestive Disease and Nutrition Center, Children's Hospital of Buffalo, 219 Bryant St., Buffalo, NY 14222, U.S.A. (e-mail: rbaker@upa.chob.edu).

The Consensus Conference was co-sponsored by the Cystic Fibrosis Foundation and by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Back to Top | Article Outline

2001 CONSENSUS COMMITTEE MEMBERS

Laura K. Bachrach, M.D.

Robert J. Beall, Ph.D.

Preston W. Campbell, III, M.D.

Susan C. Casey, B.S., R.D.

Mitchell B. Cohen, M.D.

Mary Corey, Ph.D.

W. Hobart Davies, Ph.D.

Judy A. Fulton, R.D.

Richard J. Grand, M.D.

John E. Grunow, M.D.

Dana S. Hardin, M.D.

Lesles Hendeles, Pharm.D.

James E. Heubi, M.D.

Van S. Hubbard, M.D.

Hui-Chuan Kai, Ph.D.

Sheila Innis, Ph.D.

Elisabeth Luder, Ph.D., R.D.

Karen MacGuiness, R.D.

Richard K. Mathis, M.D.

Annie McKenna, M.S., R.D., C.N.S.

Antoinette Moran, M.D.

Laurie Moyer-Mileur, Ph.D., R.D.

Kimberly O. O'Brien, Ph.D.

Hebe Quinton, M.S.

Lynne M. Quittell, M.D.

Ross W. Shepherd, M.D., FRACP

Ronald J. Sokol, M.D.

Lori J. Stark, Ph.D.

John N. Udall, Jr., M.D., Ph.D.

Babette Zemel, Ph.D.

Back to Top | Article Outline

INTRODUCTION

Patients with cystic fibrosis should have normal growth. Growth requires appropriate energy and nutrient intake, but gastrointestinal and pulmonary function and genetic potential are also important. Poor clinical outcomes are associated with undernutrition in patients with CF (1–6). The Cystic Fibrosis Foundation recognizes that attention to nutrition is an integral part of CF care. In March 2001 a Consensus Committee, co-sponsored by the Cystic Fibrosis Foundation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, met to review the literature and update a Consensus Conference Statement published in 1992 addressing these issues (7).

The CF care team should monitor growth, provide anticipatory counseling, and plan intervention strategies when patients are at risk for undernutrition or are diagnosed with nutritional failure. A registered dietitian must be a part of the team to provide the discipline-specific expertise needed for optimal nutritional management and may, along with other team members such as the physician, nurse, social worker or a psychologist, provide expertise concerning developmental and behavioral aspects of eating. Prevention and early intervention are most successful in combating nutritional failure. This document outlines the current recommendations of the Consensus Committee on how best to monitor growth and nutrition, strategies to prevent undernutrition, and interventions for patients with nutritional failure. It is based on the limited evidence available in the literature and also represents expert opinion. As with all such documents, these recommendations are likely to change as new data becomes available.

Back to Top | Article Outline

MONITORING GROWTH, BODY COMPOSITION, PUBERTAL AND BONE STATUS

Early detection of suboptimal growth allows for appropriate intervention and timely rehabilitation. Present Cystic Fibrosis Foundation (CFF) guidelines suggest that patients be seen on a routine basis, every 3 months (8). Growth and nutritional status should be monitored at these intervals (Table 1).

Table 1
Table 1
Image Tools

There are three specific times when special attention should be focused on growth and nutritional status within the scope of usual clinical care. These are: (1) the first 12 months after the diagnosis of CF for each patient; (2) birth to 12 months of age for infants diagnosed prenatally or at birth, until a normal pattern of growth (head circumference, weight, and length) is clearly established; and (3) the peripubertal growth period (girls about 9 to 16, and boys about 12 to 18 years of age). By establishing a pattern of normal growth and development after the diagnosis of CF, patients enter mid-childhood and pubertal growth well nourished, and are more likely to continue this pattern of normal growth.

Back to Top | Article Outline
Surveillance of Growth and Body Composition

Accurate, sequential measurement, plotting and interpretation of head circumference, weight, length, and height are essential to the care of children with CF. Standard anthropometric measurement techniques are well described in the literature (9–11). Mid-arm circumference and triceps skinfold thickness measurements provide clinical information about lean body mass (muscle and organ) development and subcutaneous fat (energy) stores, respectively. Each center should select and maintain anthropometric instruments, establish a detailed measurement protocol, and train those responsible for obtaining anthropometric measurements. Each clinic should also have standard protocols for cleaning the instruments between patient assessments to protect against the spread of infectious agents.

Back to Top | Article Outline
Clinical Evaluation of Measures of Growth and Body Composition
Evaluation of Growth Measurements

Weight and length (measured supine) or height (measured standing), as well as head circumference in infants, should be monitored and analyzed as growth parameters. In 2000, new NCHS/CDC growth charts were distributed for plotting weight, head circumference, length, and height (CDC web site, http://www.cdc.gov/growthcharts to download charts). The percentiles for all growth measures are expanded, compared to the 1977 charts, with two new percentile curves (97th and 3rd) for more precise evaluation at the extremes of the growth distribution. In addition, charts are provided for body mass index (BMI =(weight in kg)/(height in meters)2) with percentiles for boys and girls, age 2 to 20 years. Reference values are available for tracking head circumference in children beyond 36 months of age (12).

The 2000 edition growth charts should be used for all CF clinical care, and have been used in calculation of the CFF Patient Registry data beginning with the 1999 annual report. For optimal care, it is suggested that patients less than 24 months of age have all previously collected growth data (weight, length, head circumference) completely transferred to a 2000 edition growth chart. For patients older than 24 months, it is suggested that previously collected growth data be transferred to the 2000 growth charts for each six-month interval. Based upon clinical judgment of the pattern of growth and related clinical events (i.e., prolonged illness, use of a feeding tube, lung transplantation), more extensive growth data should be transferred to the 2000 edition growth chart.

One strong indicator of global nutritional sufficiency is if patients are growing in height to their full genetic potential (13). The genetic potential for height of each patient can be estimated by a variety of methods (14–16). This should be determined for each patient and the target height range (genetic potential related to biologic parental height) should be noted on the growth chart. Catch-up linear growth may take up to four years in children with CF diagnosed in infancy (17). A steady increase in percentile height towards the target height range indicates adequate nutritional status.

Back to Top | Article Outline
Evaluation of Weight for Height Proportion

Assessment of the weight for height proportion for an individual patient is of clinical importance. The 1992 CFF Consensus Report (7) contained some inconsistencies in how to use the recommended weight-for-height index. In practice, some CF Centers adopted the Moore modification (18) while others used the original McLaren and Read method (19). To standardize the approach to assessing relative proportion of weight for height, the committee now recommends that the term `percent ideal body weight' (abbreviated as `%IBW') and the modification of Moore et al. be used. This recommendation will be followed in subsequent discussions (Fig. 1). Users of software that calculates %IBW must know what method the program employs, since not all programs use the Moore method. Although somewhat cumbersome to calculate, %IBW remains a very sensitive index of body weight allowing for gender, age, and height. Weight-for-height percentile from NCHS/CDC growth charts is less valuable because the age of the child is ignored.

Fig. 1
Fig. 1
Image Tools

BMI is an estimate of adiposity, which should remain relatively constant throughout adulthood. However, BMI is not constant across the pediatric age range; therefore, BMI percentiles available on the 2000 CDC growth charts, rather than BMI, should be used to evaluate the pediatric patient. Guidelines for classifying underweight by BMI have been reported in the general population for adults but have not been validated in children with CF (20,21). Although the cut-off values for BMI percentiles that relate to health status are not yet well established, low BMI has been shown to be associated with increased mortality (22). Since children are growing in weight and stature, the Consensus Committee recommends that BMI percentile should be used for clinical evaluation. Just as with percentile height and weight charts, an individual BMI percentile value reflects genetic as well as health factors. Plotted sequential values indicate problems when the pattern varies from a consistent percentile. For now, it is suggested that both %IBW and BMI percentile be calculated and used for clinical care decisions. BMI percentiles are not available for children under age 2 years, so weight-for-length percentile should be used.

Evaluation of %IBW, BMI percentiles, and weight-for-length percentiles permits the identification of patients at risk for nutritional failure (Table 2). However, not all patients in the `at risk' category will have nutritional insufficiency. Use of percentiles, by definition, only describes the distribution of growth in a population. Expertise will need to be used to determine who requires closer evaluation and follow-up to prevent nutritional failure. Patients who meet the definition of nutritional failure, as outlined in Table 2, should be evaluated and treated (see below).

Table 2
Table 2
Image Tools
Back to Top | Article Outline
Evaluation of Body Composition Measurements

The two body composition measurements, mid-arm circumference and triceps skinfold thickness, are translated to age- and gender-specific percentiles using reference data from Frisancho (23). Two additional values are calculated from the mid-arm circumference and triceps measurements, and provide more accurate assessments of muscle and fat stores. These are the mid-arm muscle area (mm2) and mid-arm fat area (mm2) with age and gender reference data also provided by Frisancho (23).

Back to Top | Article Outline
Clinical Evaluation of Pubertal Development

Pubertal development is often delayed in patients with CF. This delay is usually related to growth failure and poor nutritional status, rather than to a rare primary endocrine disorder. Progressing through pubertal development is an important component of physical growth as well as psychosocial health of the child and family. In addition, studies now show that the period of pubertal growth is also very important to achieving peak bone mass and adult bone health (24). A standardized method of self-assessment (child or child/parent) (25) or physical examination (trained physician or registered nurse) (26) should be completed at least annually, in girls beginning at age 9 years and boys at age 10. Delayed puberty should be considered a marker of nutritional failure (Table 2).

Back to Top | Article Outline

CLINICAL EVALUATION OF BONE HEALTH

Bone health is of increasing interest for patients with CF, as several studies have demonstrated bone fragility in children and adults with CF (27,28). Peak bone mass is one of the major determinants of life-long bone health and is attained by early adulthood (29–31). CF with pancreatic insufficiency poses many potential risk factors for poor bone health: failure to thrive, delayed or truncated pubertal development, malabsorption of calcium, magnesium, and vitamins D and K, hepatobiliary disease, and reduced weight-bearing physical activity. Chronic use of corticosteroid medications for lung disease is also a risk factor for poor bone health, and may decrease calcium absorption and suppress linear growth (32).

Bone health can be evaluated by history (e.g., atraumatic bone fracture), physical examination (poor growth, back pain), and by radiologic and laboratory assessment. Plain radiography films (chest, long bones) that demonstrate osteopenia are usually indicative of significant loss of bone mass or lack of normal accretion of bone mass. Conventional x-ray is not nearly as sensitive or quantitative as dual energy x-ray absorptiometry (DEXA) using an age- and gender-adjusted standard deviation score (z-score) for the lumbar spine (L1–4 or L2–4). Further adjustments for small bone size and/or delayed skeletal maturation may be required to avoid over-diagnosis of low bone mass, although currently there are no standard methods for these adjustments. Comparison of scans from children or adolescents with adult reference data (T-score) is not appropriate.

Children 8 years old and older who have one of the following risk criteria for poor bone health should have an assessment of bone mass by lumbar spine DEXA: candidate for organ transplantation, post-organ transplantation, end-stage lung disease, bone fracture associated with low-impact activity (i.e., fracture with a fall from standing height), chronic use of corticosteroid medication, delayed pubertal development, and nutritional failure. In addition to the DEXA, children at risk for poor bone health should have annual serum calcium, phosphorous, intact parathyroid hormone measured in addition to routine annual 25-hydroxyvitamin D level. Also, the dietary intake of calcium and vitamin D should be determined by diet history. Abnormal blood values or suboptimal dietary intake should be corrected by treatment.

Current treatment of osteopenia or osteoporosis in children with CF is usually limited to general health measures, including optimizing growth by supplying adequate calories, general nutrition by ensuring sufficient vitamin D and K intake to normalize blood levels, encouraging calcium intake that meets the recommendations for age (33), and by fostering weight-bearing physical activity as tolerated. Antiresorptive drug therapy remains experimental, but may be used in lung transplant patients and may ultimately prove appropriate for patients with a history of low-impact bone fractures. Referral to a physician specializing in treating bone health in children may be considered.

Back to Top | Article Outline

NUTRITION MANAGEMENT IN THE WELL CHILD

Issues Related to Pancreatic Insufficiency
Identifying Pancreatic Insufficiency

Eighty-five to 90% of patients with CF have pancreatic insufficiency (PI) (34). The majority of pancreatic function must be lost before symptoms of PI are apparent (35). PI leads to malabsorption of dietary fat, protein, and other nutrients. Pancreatic functional status is a strong predictor of long-term outcome (36) and has a direct influence on nutritional status; therefore, knowing the pancreatic phenotype is useful not only in nutritional management but as a prognosticator. Specific CFTR mutations are associated with pancreatic sufficiency in a dominant fashion (see Table 3). Possessing an allele from this group offers protection even in combination with an allele normally associated with PI (37).

Table 3
Table 3
Image Tools

When the diagnosis of CF has been established, PI is often inferred by clinical signs and symptoms such as: frequent, malodorous, greasy stools, the presence of meconium ileus, or distal intestinal obstruction syndrome. Tests to document PI include: (1) duodenal intubation with stimulation; (2) 72-hour fecal fat balance study; (3) immunoreactive trypsinogen after 8 years of age; and (4) other markers as they become more widely available, such as fecal elastase-1 and fecal chymotrypsin determinations (38). Indirect tests to infer PI include low serum fat-soluble vitamins and/or low serum beta-carotene (after the introduction of fruits and vegetables). It is important to assess the pancreatic function of patients as soon as the diagnosis of CF is made. Steatorrhea may be the result of other conditions. When PI is present, enzyme, and vitamin therapy (Table 4) as well as proactive nutritional management should be started.

Table 4
Table 4
Image Tools

Some patients whose tests initially indicate that they are pancreatic sufficient (PS) become PI. PS patients should be reevaluated annually for the conversion to PI, especially if genetic testing reveals two mutations that are generally associated with PI. This evaluation can consist of monitoring growth, nutrition, and stool pattern; one or more of the tests listed above for assessing pancreatic function may be needed for more objective evidence.

Back to Top | Article Outline
Recommendation for Pancreatic Enzyme Replacement Therapy

Pancreatic enzyme replacement therapy is initiated once PI has been identified. Enzymes are given with all foods and milk products including predigested formulas and breast milk. Medium chain triglycerides (MCT) require less lipase activity than long-chain fats for efficient absorption, although lipase is still needed (39). Microsphere or microtablet preparations are preferable to powders because the acid-resistant enteric coating prevents acid-inactivation of the enzymes, and are not associated with mouth and/or perianal excoriation. Decreased pancreatic bicarbonate secretion combined with gastric acid may cause the duodenum and proximal jejunum to remain acidic, preventing dissolution of the protective coating until the capsules have bypassed a significant amount of intestinal absorptive surface. This can be treated by the administration of a histamine-2 receptor blocker or a proton pump inhibitor (40,41). Enzymes work best when taken before each meal and snack. For prolonged meal events, such as at a buffet or party, the enzymes may be more effective if distributed throughout the meal. Parents and adolescent should learn to adjust enzyme dosage according to the anticipated amount of fat in the meal or snack based on guidance from their CF team. Schools and caretakers should be aware of the need for enzymes with all meals and snacks.

Generic enzymes are not bio-equivalent to proprietary enzymes (42). Therefore it is recommended that only proprietary enzymes be prescribed and that the prescription be marked `no substitution,` or an equivalent statement.

The adequacy of enzyme therapy can be assessed subjectively by following growth parameters and stool patterns. At present the best objective test available is a 72-hour fecal fat collection with calculation of a coefficient of fat absorption. Infants taking MCT-enriched formulas or patients receiving MCT-containing enteral formulas must have stool analyzed for fat using the Jeejeebhoy method (43) to avoid false negative results. A variety of newer methods are being developed to determine the adequacy of enzyme therapy, but are not yet available for clinical use (44). This is an important research area. Tests such as fecal elastase-1 and stool chymotrypsin are measures of pancreatic function but do not establish the adequacy of enzyme replacement.

A more complete discussion of pancreatic enzyme replacement therapy can be found in the report of the Consensus Conference on Enzyme Therapy and Fibrosing Colonopathy (45). To avoid fibrosing colonopathy, it is recommended that enzyme doses should be less than 2500 lipase units/kg per meal or less than 4000 lipase units/gram fat per day (46).

Back to Top | Article Outline
Developmental Approach to Nutritional Anticipatory Guidance
Infants (First Year of Life)

Breast-feeding is recommended for most infants as the primary source of nutrition for the first year of life. Proprietary formulas can also be used. Intolerance to cow's milk, either from allergy or lactose intolerance, is no more common in patients with CF than in the general population. Often, a caloric density greater than the standard 20 kcal/ounce may be needed and can be achieved by fortifying breast milk, by concentrating formula, or by the addition of fat and/or carbohydrate. Breast or formula feeding should continue for the first 12 months of life. Thereafter, whole milk can be used in the thriving child. Solid foods should be added at 4 to 6 months developmental age according to the recommendations of the American Academy of Pediatrics. Infant cereal should be prepared with formula or breast milk, not water or juice.

Sources of fluoride and iron should be identified within the first year, in addition to the vitamin supplementation recommended for children with CF (Table 4). Supplemental fluoride and iron need to be given if the dietary intake is inadequate (47,48). Hyponatremic alkalosis may occur in the breast or formula fed infant with CF. Supplementation with sodium chloride, especially during the summer is necessary (see below).

For infants who are taking solids but not achieving their expected rate of growth, additional calories can be added to infant cereal with the addition of carbohydrate polymers (e.g., Polycose®, Ross Laboratories Division, Abbott Labs, Columbus, OH)) and/or fats such as vegetable oil, Microlipid®, (Mead Johnson, Evansville, IN) or MCT oil. As infants are introduced to table foods, it is important that families understand the concept that children with CF should eat a balanced diet that is moderate to high in fat and protein. Parents and caregivers should be aware that this advice is counter to the usual nutritional advice for children without CF.

Back to Top | Article Outline
Toddlers to Preschool Age (1–4 Years)

At this age, dietary intake and degree of physical activity vary from day to day. Routinely adding calories to table foods may help with maintaining growth at this stage. The family should buy whole milk for the child with CF and lower fat milk for other family members over two years of age. Parents should avoid giving their children with CF low fat or low calorie foods. During the second year of life children establish self-feeding skills, food preferences, and dietary habits. Mealtime is a social event as well as a nutritional one. Dietitians caring for patients with CF should inquire about feeding behaviors to promote positive interactions and to prevent negative behaviors before they become entrenched. Grazing behavior should be discouraged.

Back to Top | Article Outline
School Age (5–10 Years)

This is a high-risk period for decreased rate of growth in children with CF (49,50). Participation in activities leading to limited time for snacks and enzyme adherence, taste fatigue, and progression of disease may be responsible for this decrease in growth rate. Behavioral interventions should be considered in this age group if problematic mealtime behaviors are identified. School-age children must have a basic knowledge of physiology and practical aspects of enzyme therapy.

Back to Top | Article Outline
Adolescence (11–18 Years)

This stage is associated with high nutrient requirements due to accelerated growth, pubertal development, and high levels of physical activity. CF adolescent development and behavior reflect the general population. Pulmonary infections are more common in this period, also increasing nutritional needs. Females are at greater risk for nutritional failure (51). This is an age when confounding factors, such as CF-related diabetes or liver disease, may complicate nutrition management. Growth failure and pubertal delays may occur and come at a time of social pressure and psychosocial stress. Nutritional counseling will be more effective if directed toward the patient as well as toward the parent. Teenagers may be more receptive to efforts to improve muscular strength and body image as a justification for better nutrition than stressing weight gain and improved disease status.

Back to Top | Article Outline
Recommendations for Energy Intake and Specific Nutrients
Energy Intake

Optimal dietary intake is an essential component of nutritional care of the patient with CF especially in the presence of pancreatic insufficiency. Patients with CF often require a greater fat intake (35 to 40% of calories) than that recommended for the general population (≤30%). Energy intake should be evaluated based on the pattern of weight gain and of fat stores. There is no perfect method to estimate the caloric needs of an individual with CF. The desired clinical outcome is a steady rate of weight gain in growing children.

Back to Top | Article Outline
Fat-Soluble Vitamins and Beta Carotene

Fat malabsorption can lead to the loss of vitamins that are aggregated with fat. Patients with CF who are adequately treated with pancreatic enzymes continue to malabsorb fat-soluble vitamins. Bile acids also are necessary for absorption of fat and fat-soluble vitamins; patients with CF have malabsorption of bile acids as well as pancreatic dysfunction (52). Patients with CF who have liver disease or interruption of the enterohepatic bile acid circulation thus are at even higher risk for fat-soluble vitamin malabsorption. There is ample evidence that patients with CF become depleted of fatty substances (53–57). Recommendations for surveillance and replacement of these substances are given in Tables 5 and 4.

Table 5
Table 5
Image Tools
Back to Top | Article Outline
Beta-Carotene

Beta-carotene is a precursor of vitamin A and may also function as an antioxidant. It is uncertain whether a beta-carotene deficiency state exists in patients with CF or not. A number of studies have documented low serum levels of beta-carotene in patients with CF that, with oral supplementation, can be corrected (53,58,59). One randomized study showed a decreased number of days on antibiotics for patients taking beta-carotene, suggesting that it may play a physiologic role (59). Further evidence for a clinical deficiency state is lacking.

Back to Top | Article Outline
Vitamin A

Vitamin A is important for vision, epithelial cell integrity, epithelial proliferation, and immunity. Pancreatic lipase is required to digest retinyl esters before absorption. In cross-sectional studies between 15 and 40% of CF patients have been found to be vitamin A deficient (54,60,61). In one study, 18% of adult CF patients were found to have deficits in dark field adaptation (62). The combination of these studies suggests that Vitamin A deficiency in CF is common. Vitamin A is a negative acute phase reactant, so levels measured during acute illnesses may yield misleadingly low results (63). Thus, surveillance levels should not be drawn at the time of admission to the hospital for illness.

Back to Top | Article Outline
Vitamin D

Vitamin D functions to increase calcium absorption. Vitamin D nutriture takes on added importance because of the prevalence of osteoporosis and bone fractures among patients with CF (64). Ten to forty percent of patients with CF have been demonstrated to be deficient in vitamin D (55). Older children and adults and those residing in northern latitudes are more likely to have inadequate 25-hydroxy vitamin D levels, because of limited exposure to sunlight.

Back to Top | Article Outline
Vitamin E

Vitamin E (alpha tocopherol) is an antioxidant. Deficiency states lead to hemolytic anemia, neuromuscular degeneration, as well as retinal and cognitive deficits. Vitamin E has been reported to be low in patients with CF, even in those taking pancreatic enzymes and multivitamins, and symptomatic deficiency states have been reported (65,66). Five to ten percent of CF patients continue to have low serum vitamin E levels despite supplementation (56).

Back to Top | Article Outline
Vitamin K (Phylloquinone, Menaquinone)

Vitamin K functions in the biosynthesis of clotting factors and with osteocalcin as well as in GLA protein hydroxylation. Since measurement of serum vitamin K levels is not practical, plasma prothrombin concentration (PT) has been used as a surrogate. Although it is not widely available, PIVKA-II (Proteins Induced by Vitamin K Absence or Antagonism) is a more sensitive measure of vitamin K adequacy. Insufficiency of vitamin K leads to the formation of under γ-carboxylated vitamin K-dependent clotting factors. PIVKA-II will detect changes of a few ng/ml while PT detects changes of 100 μg/ml. Some authors suggested that vitamin K deficiency was uncommon, while others, using the more sensitive PIVKA-II, found it to be very common, even if enzymes and multivitamins are given (55,57,66,67). Colonic bacteria are a source of vitamin K. Disruption of the enteric flora by antibiotic use can reduce vitamin K levels. In a study of adults with CF who were taking oral antibiotics, vitamin K at doses of 5mg four times a week was not sufficient to correct PIVKA-II levels. This study suggests that previous recommendations for vitamin K replacement during antibiotic therapy may be inadequate (66).

Back to Top | Article Outline
Essential Fatty Acids and DHA

Biochemical essential fatty acid deficiency (EFAD) is common in patients with CF, and can occasionally be seen in PS patients as well as in those who are PI (68–71). However, clinical signs and symptoms are rare, although EFAD should be considered in young infants with failure to thrive. The triene:tetraene ratio falls in patients with EFAD. Essential fatty acids are polyunsaturated fats that can be metabolized to linoleic (n-6 series) and alpha-linolenic acid (n-3 series). Linoleic acid is further metabolized to arachidonic acid (AA), and alpha-linoleinic acid is metabolized to docosohexaenoic acid (DHA). DHA downregulates AA incorporation into phospholipid membranes. Failure of DHA to limit AA incorporation may be a factor in the increased AA seen in bronchoalveolar lavage fluid in patients with CF. There has been speculation that abnormal fatty acid metabolism is a primary problem in CF (i.e., is not secondary to fat malabsorption) (72). Whether DHA supplementation is warranted in patients with CF is the subject of careful research; no recommendations can be made at the present time. Vegetable oils such as flax, canola and soy, and cold-water marine fish are rich in linolenic acid, are a good source of energy and can be recommended. Human breast milk contains DHA and should be encouraged for infants.

Back to Top | Article Outline
Minerals and Electrolytes
Back to Top | Article Outline
Calcium

Recently, dietary calcium recommendations for the general population have been revised upward (33). There has also been an increased awareness of the high prevalence of osteopenia, osteoporosis, and an increased fracture risk in children and adults with CF. Several studies have indicated that calcium insufficiency and low bone mass are major issues of concern even in the pediatric CF population (28,73–75). To maximize skeletal accretion of calcium in children and adolescents, intake should, at a minimum, achieve levels specified by the 1997 IOM recommendations.

Back to Top | Article Outline
Iron

Iron deficiency is an issue of concern for children with CF (76–78). Ferritin is frequently used as an index of iron status. However, ferritin is an acute phase reactant and may be artificially elevated in patients with CF due to concurrent inflammation. Serum transferrin receptors are a more sensitive indicator of iron deficiency because they are not affected by inflammation, but at present, this test is not available commercially (79). Until better tests are available, it is recommended that iron status be monitored yearly in children and adolescents with CF by checking hemoglobin and hematocrit.

Back to Top | Article Outline
Zinc

Recent stable isotope studies have reported increased endogenous fecal zinc losses and decreased zinc absorption in children and infants with CF (80,81). Zinc deficiency in CF is difficult to characterize because zinc deficiency may be present when plasma zinc is in the normal range. Empiric zinc supplementation as a treatment trial for a period of six months can be considered for CF patients who are failing to thrive or have short stature. Zinc deficiency is known to affect vitamin A status, so zinc supplementation is also reasonable in CF patients with suboptimal vitamin A status or in those who report night blindness that does not respond to vitamin A therapy alone (54).

Back to Top | Article Outline
Sodium

Infants and children with CF are at risk of hyponatremia because of salt loss through the skin. The evidence in infants is limited to case reports (82,83), while sodium loss in older patients with CF has been studied in more detail (84). Patients with CF are advised to take in a high salt diet. This recommendation should be emphasized during the summer months and for those who live in hot climates. Infants without CF require 2–4 mEq/kg/d of sodium; infants with CF likely are at the upper end of this range when not exposed to heat stress. Before the introduction of complementary foods or when exposed to heat stress, babies with CF should have supplemental sodium. Historically, sodium supplements have been given using 1/8 tsp table salt (which contains approximately 11 mEq sodium). This method has the disadvantage of being imprecise and has the potential for mistakes. Sodium chloride solutions are available through pharmacies and can be dispensed more accurately.

Back to Top | Article Outline
Complementary and Alternative Medicine (CAM)

It is estimated that between 33 and 66% of CF patients have used non-traditional medicine (85,86). Interestingly, 33 to 100% of these patients report achieving benefit from these therapies. Use of herbal or dietary therapies is lower, in the range of 11 to 28%. CAM products are problematic for two reasons. First, no proof of safety or efficacy is required by U.S. law and second, there is no assurance of purity, potency, or quality.

Patients with CF and their parents may be reluctant to discuss non-traditional therapies with medical team. The American Academy of Pediatrics' Committee on Children with Disabilities published guidelines on CAM therapy that state: “To best serve the interest of children, it is important to maintain a scientific perspective, provide balanced advice about treatment options, guard against bias, and to establish and maintain a trusting relationship with families” (87). It is important to ask patients with CF and their parents about CAM in a non-judgmental way.

Back to Top | Article Outline

EVALUATION OF PATIENTS WITH NUTRITIONAL FAILURE AND THOSE AT RISK

Definition of Nutritional Failure and Patients at Risk

Criteria for considering patients to have nutritional failure and to be at risk for nutritional failure are given in Table 2. When poor growth is identified, patients should be seen more frequently than the every three-month Center visits outlined in the Practice Guidelines for routine surveillance. Infants should be seen every two to four weeks, and children over age two years should be seen every four to six weeks. These visits should include medical, behavioral, and nutritional assessment, education and intervention as outlined in Figure 2. Nutrition intervention should aim at achieving the patient's target goal for both weight-for-height proportion and genetic height potential.

Fig. 2
Fig. 2
Image Tools
Back to Top | Article Outline
Evaluation of Co-Morbid Medical Conditions

Medical as well as nutritional and behavioral factors should always be considered in the patient who fails to gain weight. If pulmonary or sinus disease are active, these should be treated. Gastroesophageal reflux disease (GERD) occurs with increased frequency in patients with CF of all ages, and can cause both pulmonary symptoms and poor growth (88,89). An extensive review of the literature and recommendations for diagnosis and treatment of GERD in infants and children has recently been published (90). CF related diabetes (CFRD) with or without fasting hyperglycemia can cause poor growth. Insulinopenia causes protein catabolism (91). An oral glucose tolerance test should be considered strongly in all patients with poor growth. The reader is referred to the recent Consensus Conference for management of CFRD (92). Non-pancreatic causes of malabsorption may also contribute to poor growth. These include CF-related hepatobiliary disease (93), infectious enteritis, bacterial overgrowth of the small intestine, or intestinal mucosal problems such as Crohn's or celiac disease. Intestinal resection with short bowel syndrome, which may occur following surgery for meconium ileus, can worsen fat malabsorption and result in poor essential fatty acid status and poor growth (94). Fibrosing colonopathy should be considered in patients who have received pancreatic enzyme supplements at doses greater than 2,500 lipase units/kg/meal (45). Referral to a gastroenterologist may be warranted for patients with persistent poor growth.

An important and easily treatable cause of poor growth and nutritional status in the patient with PI is ineffective pancreatic enzyme replacement therapy. In addition, inactivation of enzymes by an acidic duodenal environment may render even an appropriate dose ineffective.

Back to Top | Article Outline
Behavioral Evaluation

Presence of ineffective feeding behaviors and parenting strategies should be assessed early in the evaluation of patients with nutritional failure. The Behavioral Pediatrics Feeding Assessment Scale is a self-reported measure of mealtime problems (95). It is easy to use and appears to have adequate psychometric properties to be used clinically to identify problem behaviors that can be addressed to improve caloric intake. Research on eating in adolescents with CF has primarily focused on assessment of eating disorders or disturbances of body image, and no excess of these problems has been identified. However, concomitant anorexia nervosa should be considered in the adolescent with CF with very low body weight.

Back to Top | Article Outline
Dietary Evaluation

Dietary intake can be difficult to assess if patients are eating breakfast and/or lunch at school, meals are being served by daycare centers, sitters or relatives, or if the parents are working alternate shifts and meals are not eaten together. Specific questions should be asked about the volume of juice, flavored sugar drinks and carbonated beverages ingested, as well as the fat content and volume of milk. Parents should be questioned about fat-free or low-fat foods, which may be used “on the run” when enzymes are unavailable. Meals may be skipped altogether if the child is too rushed to eat breakfast, dislikes school lunches, or has an activity schedule which interferes with dinner. A 24-hour dietary recall provides a qualitative assessment of dietary patterns and is easily obtained in the office setting. A prospective 3 to 5 day diet record must be collected for any quantitative assessment of energy and nutrient intake. Medical factors such as iron deficiency or constipation should be considered in children with poor appetites.

Back to Top | Article Outline
Interventions for Patients With Nutritional Failure
Behavioral Intervention

If problematic mealtime behaviors as described under behavioral assessment are identified, behavioral intervention may be used in conjunction with nutritional intervention to improve oral intake. Behavioral interventions have been demonstrated to be effective in changing feeding dynamics for children ages 3 to 12 years and their parents in a research setting (96) and can be used in the clinical setting. The first behavioral strategy is to gradually increase calories by working on one meal at a time. A second strategy involves teaching parents alternative ways of responding to their child who eats slowly or negotiates what he or she will eat. A third strategy is to identify appropriate rewards for eating the expected amount of food at each meal. Referral for more in-depth behavioral therapy should be considered.

Back to Top | Article Outline
Dietary Interventions
Back to Top | Article Outline
Oral Supplements

Generally, nutritional interventions start with addition of high-calorie foods to the patient's regular diet and use of nutritional energy supplements. Positive weight gain was demonstrated by one randomized study and one case-controlled study of nutritional counseling and homemade high-calorie foods (97,98). Two studies using commercially available supplements failed to improve nutritional status (99,100). Use of energy supplements is warranted, but surveillance is necessary to assure that they are not used as substitutes for normal food intake. The convenience of pre-packaged supplements may be useful for patients with busy schedules.

Back to Top | Article Outline
Enteral Feedings
Back to Top | Article Outline
Introduction to Family and Initiation

Supplemental enteral feedings should be started when oral supplementation fails to result in weight gain. The purpose and goals of enteral feedings should be explained to the patient and family, and their acceptance and commitment to this intervention should be realistically assessed. Enteral feedings should be presented as a positive treatment, not as a threat or “the beginning of the end”. Likewise, enteral feedings should be presented as a supportive therapy to improve quality of life and outcome. A possible way of assuring that families and patients understand this concept is to introduce the idea of enteral feeds at diagnosis or early in the course of CF, before nutritional failure is present. Enteral feeds should be presented as one of many treatment modalities to improve nutritional status and quality of life. The family should be provided with concrete information on the types of feeding tubes and formulas and how feeding systems work.

Since no good data exist to demonstrate the superiority of one type of enteral access over another, the choice of tube and technique for its placement (nasogastric, orogastric, gastrostomy, or jejunostomy) should be based on the experience of the Center. Some clinicians believe that the presence and/or severity of GERD should be assessed before initiation of enteral feedings, and if severe GERD is present, an antireflux procedure should be performed at the time of gastrostomy placement. Further research is needed to clarify the risks and benefits of this approach. Pulmonary health should be maximized before placement of all permanent tubes, and a plan for management of postoperative pain should be made before the procedure.

Back to Top | Article Outline
Formulas and Caloric Goals

Standard (complete protein, long-chain fat) formulas typically are well tolerated. Calorically dense formulas (1.5–2.0 kcal/cc) usually are necessary for provision of adequate calories. The data are unclear as to whether formulas with medium-chain triglycerides are beneficial. Some practitioners find semi-elemental formulas helpful in patients who have excessive anorexia, bloating or nausea. Nocturnal infusion is encouraged to promote normal eating patterns during the day. Initially, 30 to 50% of estimated energy requirements should be provided overnight. Anecdotally, a total daily caloric goal of 120 to 150 kcal/kg/d may be needed in infants to achieve catch-up growth and promote optimal lung growth. The amount of calories delivered should then be titrated based on the rate of weight gain, fat stores, and growth. Very low-fat, elemental formulas may be used without enzyme supplements for patient who have endotracheal tubes in place and should be given by continuous infusion to maximize absorption.

Back to Top | Article Outline
Use of Enzymes With Enteral Feedings

There are inadequate data on the appropriate dosing of pancreatic enzymes with overnight enteral feedings. One study found that complete formula with enzymes given before and after feedings and semi-elemental (hydrolyzed protein, medium chain triglyceride-enriched) formula given without enzymes, were equally well absorbed, although there was a trend towards less absorption of long chain fat and protein in the semi-elemental formula group (101). One study indicated that enzyme replacement improved fat absorption in infants receiving semi-elemental formulas (102). Another study of three formulas containing 0, 32, and 58% of calories as fat demonstrated 82 to 85% fat absorption when the usual mealtime dose of enzymes was given orally both before and mid-way through 8-hour nocturnal enteral feedings (103). The Consensus Committee recommends that pancreatic enzyme supplements be taken orally in the usual pre-meal dose before all nocturnal enteral feedings (with the exception of very low-fat, elemental formulas, as above). Additional doses may need to be given mid-way through or at the end of a feeding. Further research is needed to define the optimal method to provide pancreatic enzyme supplementation with enteral feedings.

Back to Top | Article Outline
Complications

Complications may be associated with enteral feedings. Patients on enteral feedings should be monitored for carbohydrate intolerance. Once the full caloric goal has been achieved, blood sugars should be checked two to three hours into the feeding and at the end of the feeding on two separate nights. Insulin should be added if these blood sugars are greater than 180 mg/dl. This schedule of blood sugar monitoring should be repeated when a patient is ill, receiving steroids, or if the patient is not gaining weight. Patients with permanent feeding tubes should have their skin evaluated for local breakdown. Patients with excessive bloating may benefit from the addition of pro-kinetic agents or use of a semi-elemental formula.

Back to Top | Article Outline
Anabolic Agents

Insulin promotes anabolism as well as lowering blood sugar. Proteolysis is higher in patients with CF than controls, but those with CF exhibit resistance to the anabolic effects of insulin (104). Insulin therapy improves weight in patients with CFRD and fasting hyperglycemia (105). It is unknown whether insulin therapy improves weight and muscle mass in malnourished patients who have CFRD without fasting hyperglycemia, but treatment of these patients with insulin should be considered on a case-by-case basis. One group of children treated with growth hormone had increased height and weight velocity, lean body mass, and pulmonary function and had decreased hospitalizations (106). However, since height and weight increased proportionately, treated patients remained significantly underweight at the end of one year of treatment, suggesting that this expensive intervention is not a replacement for nutritional intervention. Growth hormone can also reverse protein catabolism and decrease circulating inflammatory cytokines (107). Longitudinal studies are needed to determine if the improvements are sustained. There may be a role for growth hormone therapy in selected children with CF. Several small studies have demonstrated increased appetite and weight gain in patients treated with megestrol acetate (108–110), although side effects such as adrenal suppression, insulin resistance, development of Cushingoid facies, insomnia, hyperactivity, and hypertension have been noted. Improvements do not appear to be sustained after the drug is discontinued. Until more data become available that show the benefits outweigh the risks, anabolic agents cannot be recommended for routine use in CF.

Back to Top | Article Outline

CONCLUSION

Our aim is to have every child with CF achieve normal growth and development. This requires regular and accurate surveillance, adequate calories and nutrients, and a plan for prompt intervention when growth is suboptimal. This is best accomplished with a multidisciplinary team approach at an accredited CF Center. This document is intended to present our best recommendations based on current knowledge. However, cystic fibrosis and nutrition research is needed in many areas before guidelines can be made based on evidence and not consensus opinion.

Back to Top | Article Outline

REFERENCES

1. Kraemer R, Rudeberg A, Hadom B, et al. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatr Scand 1978; 67:33–7.

2. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988; 41:588–91.

3. Kerem E, Reisman J, Corey M, Canny GJ, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187–91.

4. Dalzell AM, Shepherd RW, Dean SB, et al. Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. J Pediatr Gastroenterol Nutr 1992; 15:141–145.

5. Pencharz PB, Durie PR. Nutritional management of cystic fibrosis. Ann Rev Nutr 1993; 13:111–36.

6. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc 2001; 101:438–42.

7. Ramsey BW, Farrell PM, Pencharz P, Consensus Committee. Nutritional assessment and management in cystic fibrosis: a consensus report. Am J Clin Nutr 1992; 55:108–16.

8. Clinical Practice Guidelines for Cystic Fibrosis, 1997; Cystic Fibrosis Foundation, Bethesda, MD.

9. Gordon CC, Chumlea WC, Roche AF. Stature, recumbent length and weight. In: Lohman TG, Roche AF, Martorell R, eds. Anthropometric standardization reference manual. Champaign IL: Human Kinetics Books, 1988:3–8.

10. Callaway CW, Chumlea WC, Buchard C. et al. Circumferences. In: Lohman TG, Roche AF, Martorell R, eds. Anthropometric standardization reference manual. Champaign IL: Human Kinetics Books, 1988:51–52.

11. Harrison GG, Buskirk ER, Carter JEL, et al. Skinfold Thicknesses and measurement technique. In: Lohman TG, Roche AF, Martorell R, eds. Anthropometric standardization reference manual. Champaign IL: Human Kinetics Books, 1988:56–57.

12. Roche, AF, Mujherjee D, Guo S, et al. Head circumference reference data: birth to 18 years. Pediatrics 1987; 79:706–12.

13. Wright CM, Cheetham TD. The strengths and limitations of parental heights as a predictor of attained height. Arch Dis Child 1999; 81:257–60.

14. Garn SM, Rohman CG. Interaction of nutrition and genetics in the timing of growth and development. Pediatr Clin N Am 1966; 13:353–80.

15. Himes JH, Roche AF, Thissen D, et al. Parent-specific adjustment for evaluation of recumbent length and stature of children. Pediatrics 1985; 75:304–13.

16. Falkner F, Tanner JM, eds. Human Growth, second edition, Vol 3, pp 104–107, New York, Plenum Press 1986.

17. Farrell PM, Kosorok MR, Rock MJ, et al. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 2001; 107:1–13.

18. Moore BJ, Durie PR, Forstner GG, et al. The assessment of nutritional status in children. Nutr Res 1985; 57:97–99.

19. McLaren DS, Read WW. Weight/length classification of nutritional status. Lancet 1975; 2:219–21.

20. U.S. Department of Agriculture, Agriculture Research Service Dietary Guideline Advisory Committee. Report of the Dietary Guidelines for Americans. 1995, to the Secretary of Health and Human Services and the Secretary of Agriculture, Beltsville, MD: USDA, 1995.

21. World Health Organization. Diet, nutrition, and the prevention of chronic diseases: Report of a WHO study group. Geneva: WHO Technical Report Series: 1990; no. 797:69–75.

22. Troiano RP, Frongillo EA, Sobal J, et al. The relationship between body weight and mortality: a quantitative analysis of combine information from existing studies. Int J Obes 1996; 20:63–75.

23. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr 1981; 34:2540–45.

24. Bailey DA, McKaym HA, Mirwald RL, et al. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the University of Saskatchewan bone mineral accrual study. J Bone Miner Res 1999; 14:1672–79.

25. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth & Adolesc 1980; 9:271–80.

26. Tanner JM. Growth at Adolescence, 2nd edition. Oxford: Blackwell Scientific Pub, 1962.

27. Henderson RC, Madsen CD. Bone density in children and adolescents with cystic fibrosis. J Pediatr 1996; 128:28–34.

28. Bhudhikanok GS, Wang M-C, Marcus R, et al. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatr 1998; 133:18–27.

29. Bachrach LK. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001; 12:22–28.

30. National Institutes of Health Consensus Development Conference Statement: Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consens Statement 2000, March 27–29;17(1):1–36.

31. Matkovic V. Calcium and peak bone mass. J Intern Med 1992; 231:151–60.

32. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, et al. Persistent growth impairment in children with cystic fibrosis following treatment with alternate-day prednisone. N Engl J Med 2000; 342:851–59.

33. Institute of Medicine. Dietary Reference Intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington DC: National Academy Press, 1997.

34. Couper RT, Corey M, Moore DJ, et al. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic insufficiency. Pediatr Res 1992: 32;179–82.

35. Gaskin KJ, Durie PR, Lee L, et al. Colipase and lipase secretion in childhood-onset pancreatic insufficiency: delineation of patients with steatorrhea secondary to relative colipase deficiency. Gastroenterol 1984: 86;1–7.

36. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis-analysis of the most common mutation (DF508). N Engl J Med 1990: 232;1517–22.

37. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992: 50;1175–84.

38. Borowitz D, Evidence for the diagnosis of pancreatic sufficiency. Pediatr Pulmonol 2000; 29:167–8.

39. Caliari S, Benini L, Sembenini C, et al. Medium-chain triglyceride absorption in patients with pancreatic insufficiency. Scand J Gastroenterol 1996: 31;90–4.

40. Zentler-Munro PL, Fine DR, Batten JC, et al. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilization in pancreatic steatorrhea due to cystic fibrosis. Gut 1985: 26;892–901.

41. Heijerman HG, Lamers CB, Bakker W. Omeprazole enhances the efficacy of pancreatin (Pancrease) in cystic fibrosis. Ann Int Med 1991; 114:200–01.

42. Hendeles L, Dorf A, Stecenko A, et al. Treatment failure after substitution of generic pancrelipase capsules. JAMA 1990: 263; 2459–61.

43. Jeejeebhoy KN, Ahmed S, Kozak G. Determination of faecal fats containing both medium chain and long-chain triglycerides and fatty acids. Clin Biochem 1970; 3:157–63.

44. Van Dijk-van Aalst K, Van den Driessche M, van der Schoor S, et al. 13C Mixed triglyceride breath test: a noninvasive method to assess lipase activity in children. J Pediatr Gastroenterol Nutr 2001: 32;579–85.

45. Borowitz D, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 1995; 127:681–84.

46. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1998: 336;1283–1289.

47. Committee on Nutrition, R Kleinman (Ed.), Pediatric Nutrition Handbook, 4th edition, American Academy of Pediatrics, pp. 525, 1998.

48. Center for Disease Control, Recommendations to prevent and control iron deficiency in the United States. MMWR, Apr 3, 1998, 47 (rr-3): 1–36.

49. Lai HC, Corey M, FitzSimmons S, et al. Comparison of growth status in patients with cystic fibrosis between United States and Canada. Am J Clin Nutr 1999; 69:531–8.

50. Karlberg J, Kjellmer I, Kristiansson B. Linear growth in children with cystic fibrosis: I birth to 8 years of age. Acta Paeditr Scanda 1991: 80;508–14.

51. Lai H-C, Kasorok MR, Sondel SA, et al. Growth status of children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry: Evaluation of various criteria used to identify malnutrition. J Pediatr 1998: 132;478–85.

52. Weber AM, Roy CC, Morin CL, et al. Malabsorption of bile acids in children with cystic fibrosis. N Engl J Med 1973: 289;1001–5.

53. Winklhofer-Roob BM, van't Hof MA, Shmerling DH. Response to oral beta-carotene supplementation in patients with cystic fibrosis: a 16-month follow-up study. Acta Paediatr 1995; 84:1132–36.

54. Palin D, Underwood BA, Denning CR. Effect of oral zinc supplementation on plasma levels of vitamin A and retinol-binding protein in cystic fibrosis. Am J Clin Nutr 1979; 32:1253–59.

55. Feranchak AP, Sontag MK, Wagener JS, et al. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 1999; 135:601–10.

56. Winklhofer-Roob BM, van't Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Am J Clin Nutr 1996; 63:722–28.

57. Rashid M, Durie P, Andrew M, et al. Prevalence of vitamin K deficiency in cystic fibrosis. Am J Clin Nutr 1999; 70:378–82.

58. Lepage G, Champagne J, Ronco N, et al. Supplementation with carotentoids corrects increased lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 1996; 64:87–93.

59. Renner S, Rath R, Rust P, et al. Effects of beta-carotene supplementation for six-months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax 2001; 56:48–52.

60. Solomons NW, Wagonfeld JB, Rieger C, et al. Some biochemical indices of nutrition in treated cystic fibrosis patients. Am J Clin Nutr 1981; 34:462–74.

61. Lindblad A, Diczfalusy U, Hulcrantz R, et al. Vitamin A Concentration in the liver decreases with age in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1997; 24:264–70.

62. Rayner RJ, Tyrell JC, Hiller EJ, et al. Night blindness and conjunctival xerosis caused by vitamin A deficiency in patients with cystic fibrosis. Arch Dis Child 1989; 64:1151–56.

63. Duggan C, Andrew CA, Agil A, et al. Am J Clin Nutr. Vitamin A status in acute exacerbations of cystic fibrosis. Am J Clin Nutr 1996; 64:635–39.

64. Hahn TJ, Squires AE, Halstead LR, et al. Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. J Pediatr 1979: 94;38–42.

65. Winklhofer-Roob BM, Tuchschmid PE, Molinari L, et al. Response to a single oral dose of all-rac-alpha-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals. Am J Clin Nutr 1996; 63:717–21.

66. Beker LT, Ahrens RA, Fink RJ, et al. Effect of vitamin K-1 supplementation on vitamin K status in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1997; 24:512–17.

67. Wilson DC, Rashid M, Durie PR, et al. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr 2001; 138:851–55.

68. Roigers V, Dab I, Brokaert R, et al. Long-chain nonesterified fatty acid patterns in plasma of cystic fibrosis patients and their parents. Pediatr Res 1980; 14:1088–91.

69. Christophe AB, Warwick WJ, Holman RT. Serum fatty acid profiles in cystic fibrosis patients and their patrents. Lipids 1994; 29:569–75.

70. Roulet M, Frascarolo P, Rappaz I, et al. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997: 156:952–56.

71. Lloyd-Still JD, Bibus DM, Power CA, et al. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr 1996; 85:1426–32.

72. Freedman SD, Katz MH, Parker EM, et al. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in CFTR −/− mice. Proc Natl Acad Sci USA 1999; 96:13995–14000.

73. Bhudhikanok GS, Lim J, Marcus R, et al. Correlates of osteopenia in patients with cystic fibrosis. Pediatrics 1996: 9;103–11.

74. Henderson RC, Madsen CD. Bone mineral content and body composition in children and adults with cystic fibrosis. Pediatr Pulmonol 1999: 27;80–4.

75. Mortensen LA, Chan GM, Alder SC, et al. Bone mineral status in prepubertal children with cystic fibrosis. J Pediatr 2000: 136; 648–52.

76. Keevil B, Rowlands D, Burton I, et al. Assessment of iron status in cystic fibrosis patients. Ann Clin Biochem 2000: 37;662–65.

77. Alter JL, Hebst JJ, Landaw SA, et al. Relative anemia and iron deficiency in cystic fibrosis. Pediatr 1983: 71;810–14.

78. Ehrhardt P, Miller MG, Littlewood JM. Iron deficiency in cystic fibrosis. Arch Dis Child 1987: 62;185–87.

79. Keevil B, Rowlands D, Burton I, et al. Assessment of iron status in cystic fibrosis patients. Ann Clin Biochem 2000: 37;662–65.

80. Easley D, Krebs N, Jefferson M, et al, Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 1998: 26;136–39.

81. Krebs NF, Westcott JE, Arnold TD, et al. Abnormalities of zinc homeostasis in young infants with cystic fibrosis. Pediatr Res 2000: 48;256–61.

82. Di Sant Agnese PA, Salt depletion in cold weather in infants with cystic fibrosis. JAMA 1960: 84;2014–21.

83. Laughlin JJ, Brady MS, Eigen H. Changing feeding trends as a cause of electrolyte depletion in infants with cystic fibrosis. Pediatr 1981; 68:203–207.

84. Legris GJ, Dearborn D, Stern RC, et al. Sodium space and intravascular volume: Dietary sodium effects in cystic fibrosis and healthy adolescent subjects. Pediatr 1998: 101;48–568.

85. Stern RC, Canda ER, Doershuk CF. Use of nonmedical treatment by cystic fibrosis patients. J Adolesc Health 1992; 13:612–15.

86. Marcus M, Lee SK, Lai HC. Use of alternative medicines in children and adults with CF. Building Block 2000; 24:12–14.

87. Committee on Children with Disabilities, American Academy of Pediatrics, Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Pediatrics 2001:107;598–601.

88. Malfroot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow-up. Arch Dis Child 1991: 66;1339–45.

89. Scott RB, O'Laughlin EV, Gall DG. Gastroesophageal reflux in patients with cystic fibrosis. J Pediatr 1985; 106:223–27.

90. Rudolph CD et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children. Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001: 32;suppl 2 S1–S31.

91. Moran A, Doherty L, Wang X, et al. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1988; 133:10–17.

92. Moran A, Hardin D, Rodman D, et al. Diagnosis, Screening and management of cystic fibrosis related diabetes mellitus: A consensus report. Diabet Res and Clin Pract 1999; 45:61–73.

93. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 1999;28 Suppl 1:S1–13.

94. Lai HC, Kosorok MR, Laxova A, et al. Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus diagnosed early through neonatal screening. Pediatrics 2000; 105:53–61.

95. Crist W, McDonnell P, Beck M, et al. Behavior at mealtimes in the young child with cystic fibrosis. J Devel Behav Pediatr 1994; 15:157–61.

96. Stark LJ, Jelalian E, Powers SW, et al. Parent and child mealtime behavior in families of children with cystic fibrosis. J Pediatr 2000: 136;195–200.

97. Hanning RM, Blimkie C, Bar-Or O et al, Relationships among nutritional status and skeletal respiratory muscle function in cystic fibrosis: does early dietary supplementation make a difference. Am J Clin Nutr 1993; 57:580-k.

98. Parsons HG, Beaudry P, Dumas A, et al. Energy needs and growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1983; 2:44–9.

99. Kalnins D, Durie PR, Corey M, et al. Are oral dietary supplements effective in the nutritional management of adolescents and adults with CF. Pediatr Pulmonol 1996;Suppl 11:314–5.

100. Rettammel AL, Marcus M, Farrell PM, et al. Oral supplementation with a high-fat, high-energy product improves nutritional status and alters serum lipids in patients with cystic fibrosis. J Am Diet Assoc 1995; 95:454–9.

101. Erskine JM, Lingard CD, Sontag MK, et al. Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and non-elemental formula. J Pediatr 1998; 132:265–9.

102. Durie PD, Newth C, Forstner G, et al. Malabsorption of medium-chain triglycerides in infants with cystic fibrosis: correction with pancreatic enzyme supplements. J Pediatr 1980:862–4.

103. Kane RE, Hobbs PJ, Black PG. Comparison of low, medium and high carbohydrate formulas for nighttime enteral feedings in cystic fibrosis patients. J Parent Ent Nutr 1990; 14:47–52.

104. Hardin DS, LeBlanc A, Lukenbaugh S, et al. Proteolysis associated with insulin resistance in cystic fibrosis. Pediatr 1998; 101:433–37.

105. Lanng S, Thorsteinsson B, Nerup J, et al. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994; 83:849–53.

106. Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone improves clinical status in pre-pubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001; 139:636–42.

107. Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone decreases protein catabolism in children with cystic fibrosis. J Clin Endocrinol Metab 2001; 86;4424–28.

108. Marchand V, Baker SS, Stard TJ, et al. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2000; 31:264–69.

109. Newkirk M, Martinez JC, Ewig J, et al. Adrenal suppression in children with cystic fibrosis treated with megestrol acetate (Megace). Pediatr Pulmonol 2001;Suppl 20;323.

110. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Food and Nutrition Board, Institute of Medicine, National Academy Press, Washington, DC, 2001.

Cited By:

This article has been cited 145 time(s).

Journal of Animal Science
The growing pancreatic duct ligated pig as a model for exocrine pancreatic insufficiency in children: Investigations to achieve sufficient vitamin A and vitamin E supply
Mosseler, A; Schwarzmaier, T; Grunemann, J; Gregory, PC; Holtershinken, M; Kamphues, J
Journal of Animal Science, 90(): 321-323.
10.2527/jas53775
CrossRef
Journal of Cystic Fibrosis
Dietary essential amino acids are highly anabolic in pediatric patients with cystic fibrosis
Engelen, MPKJ; Com, G; Wolfe, RR; Deutz, NEP
Journal of Cystic Fibrosis, 12(5): 445-453.
10.1016/j.jcf.2012.12.011
CrossRef
Cochrane Database of Systematic Reviews
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
Thaker, V; Haagensen, AL; Carter, B; Fedorowicz, Z; Houston, BW
Cochrane Database of Systematic Reviews, (6): -.
ARTN CD008901
CrossRef
Clinical Nutrition
Use of body mass index percentile to identify fat-free mass depletion in children with cystic fibrosis
Engelen, MPKJ; Schroder, R; Van der Hoorn, K; Deutz, NEP; Com, G
Clinical Nutrition, 31(6): 927-933.
10.1016/j.clnu.2012.04.012
CrossRef
Journal of Cystic Fibrosis
Oxidative stress in stable cystic fibrosis patients: Do we need higher antioxidant plasma levels?
Lezo, A; Biasi, F; Massarenti, P; Calabrese, R; Poli, G; Santini, B; Bignamini, E
Journal of Cystic Fibrosis, 12(1): 35-41.
10.1016/j.jcf.2012.06.002
CrossRef
American Journal of Respiratory and Critical Care Medicine
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Davies, JC; Wainwright, CE; Canny, GJ; Chilvers, MA; Howenstine, MS; Munck, A; Mainz, JG; Rodriguez, S; Li, HH; Yen, K; Ordonez, CL; Ahrens, R
American Journal of Respiratory and Critical Care Medicine, 187(): 1219-1225.
10.1164/rccm.201301-0153OC
CrossRef
European Journal of Clinical Nutrition
The use of air displacement plethysmography in children and adolescents with cystic fibrosis
Murphy, AJ; Buntain, HM; Wong, JCH; Greer, RM; Wainwright, CE; Davies, PSW
European Journal of Clinical Nutrition, 58(7): 985-989.
10.1038/sj.ejcn.1601919
CrossRef
Journal of Clinical Endocrinology & Metabolism
Consensus statement: Guide to bone health and disease in cystic fibrosis
Aris, RM; Merkel, PA; Bachrach, LK; Borowitz, DS; Boyle, MP; Elkin, SL; Guise, TA; Hardin, DS; Haworth, CS; Holick, MF; Joseph, PM; O'Brien, K; Tullis, E; Watts, NB; White, TB
Journal of Clinical Endocrinology & Metabolism, 90(3): 1888-1896.
10.1210/jc.2004-1629
CrossRef
Free Radical Biology and Medicine
Antioxidants in cystic fibrosis - Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003
Cantin, AM; White, TB; Cross, CE; Forman, HJ; Sokol, RJ; Borowitz, D
Free Radical Biology and Medicine, 42(1): 15-31.
10.1016/j.freeadbiomed.2006.09.022
CrossRef
American Journal of Clinical Nutrition
Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation
Rovner, AJ; Stallings, VA; Schall, JI; Leonard, MB; Zemel, BS
American Journal of Clinical Nutrition, 86(6): 1694-1699.

Pediatric Diabetes
Management of cystic fibrosis-related diabetes in children and adolescents
O'Riordan, SMP; Robinson, PD; Donaghue, KC; Moran, A
Pediatric Diabetes, 10(): 43-50.
10.1111/j.1399-5448.2009.00587.x
CrossRef
Journal of Thoracic and Cardiovascular Surgery
Genetic factors are important determinants of impaired growth after infant cardiac surgery
Burnham, N; Ittenbach, RF; Stallings, VA; Gerdes, M; Zackai, E; Bernbaum, J; Clancy, RR; Gaynor, JW
Journal of Thoracic and Cardiovascular Surgery, 140(1): 144-149.
10.1016/j.jtcvs.2010.01.003
CrossRef
Jornal Brasileiro De Pneumologia
Predictors of oxygen desaturation during the six-minute walk test in patients with cystic fibrosis
Ziegler, B; Rovedder, PME; Oliveira, CL; Schuh, SJ; Silva, FAE; Dalcin, PDR
Jornal Brasileiro De Pneumologia, 35(): 957-965.

Jornal Brasileiro De Pneumologia
Association between nutritional status and dietary intake in patients with cystic fibrosis
Simon, MISD; Drehmer, M; Menna-Barreto, SS
Jornal Brasileiro De Pneumologia, 35(): 966-972.

American Journal of Clinical Nutrition
Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis
Graham-Maar, RC; Schall, JI; Stettler, N; Zemel, BS; Stallings, VA
American Journal of Clinical Nutrition, 84(1): 174-182.

Pediatrics
Growth and health in children with moderate-to-severe cerebral palsy
Stevenson, RD; Conaway, M; Chumlea, WC; Rosenbaum, P; Fung, EB; Henderson, RC; Worley, G; Liptak, G; O'Donnell, M; Samson-Fang, L; Stallings, VA
Pediatrics, 118(3): 1010-1018.
10.1542/peds.2006-0298
CrossRef
Archivos Argentinos De Pediatria
A consensus on diagnosis and treatment of cystic fibrosis: Is it of interest for the pediatrician?
Segal, E
Archivos Argentinos De Pediatria, 106(4): 293-294.

American Journal of Clinical Nutrition
Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis
Iuliano, L; Monticolo, R; Straface, G; Zullo, S; Galli, F; Boaz, M; Quattrucci, S
American Journal of Clinical Nutrition, 90(3): 477-484.
10.3945/ajcn.2009.27757
CrossRef
Archives of Pediatrics & Adolescent Medicine
Randomized Clinical Trial of Behavioral Intervention and Nutrition Education to Improve Caloric Intake and Weight in Children With Cystic Fibrosis
Stark, LJ; Quittner, AL; Powers, SW; Opipari-Arrigan, L; Bean, JA; Duggan, C; Stallings, VA
Archives of Pediatrics & Adolescent Medicine, 163(): 915-921.

Cochrane Database of Systematic Reviews
Vitamin D supplementation for cystic fibrosis
Ferguson, JH; Chang, AB
Cochrane Database of Systematic Reviews, (4): -.
ARTN CD007298
CrossRef
Journal of the American Dietetic Association
Single-gene autosomal recessive disorders and Prader-Willi syndrome: An update for food and nutrition professionals
Isaacs, JS; Zand, DJ
Journal of the American Dietetic Association, 107(3): 466-478.
10.1016/j.jada.2006.12.006
CrossRef
Journal of Pediatrics
Management of Infants with Cystic Fibrosis: A Summary of the Evidence for the Cystic Fibrosis Foundation Working Group on Care of Infants with Cystic Fibrosis
Robinson, KA; Saldanha, IJ; Mckoy, NA
Journal of Pediatrics, 155(6): S94-S105.
10.1016/j.jpeds.2009.09.002
CrossRef
Journal of Pediatric Psychology
Description of a Standardized Nutrition Classification Plan and its Relation to Nutritional Outcomes in Children with Cystic Fibrosis
Leonard, A; Davis, E; Rosenstein, BJ; Zeitlin, PL; Paranjape, SM; Peeler, D; Maynard, C; Mogayzel, PJ
Journal of Pediatric Psychology, 35(1): 6-13.
10.1093/jpepsy/jsp029
CrossRef
Proceedings of the Nutrition Society
Can nutrition counselling be more behavioural? Lessons learned from dietary management of cystic fibrosis
Stark, LJ
Proceedings of the Nutrition Society, 62(4): 793-799.
10.1079/PNS2003294
CrossRef
Journal of the Royal Society of Medicine
Vitamin K in cystic fibrosis
Conway, SP
Journal of the Royal Society of Medicine, 97(): 48-51.

American Journal of Clinical Nutrition
Nutritional status is an important predictor of diaphragm strength in young patients with cystic fibrosis
Hart, N; Tounian, P; Clement, A; Boule, M; Polkey, MI; Lofaso, F; Fauroux, B
American Journal of Clinical Nutrition, 80(5): 1201-1206.

Pediatric Gastroenterology 2004
Evaluation of the delta-F508 mutation and of pancreatic function and clinical characteristics of patients with cystic fibrosis
Galvao, LC; Ribeiro, AF; Rodrigues, AAC; Fernandes, MM; Bertuzzo, C; Melo, EV
Pediatric Gastroenterology 2004, (): 593-598.

Journal of Pediatrics
Combining unprotected pancreatic enzymes with pH-sensitive enteric-coated microspheres does not improve nutrient digestion in patients with cystic fibrosis
Kalnins, D; Corey, M; Ellis, L; Durie, PR; Pencharz, PB
Journal of Pediatrics, 146(4): 489-493.
10.1016/j.jpeds.2004.10.063
CrossRef
Journal of Nutrition
Evidence of choline depletion and reduced betaine and dimethylglycine with increased homocysteine in plasma of children with cystic fibrosis
Innis, SM; Hasman, D
Journal of Nutrition, 136(8): 2226-2231.

Journal of Clinical Endocrinology & Metabolism
Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: Results of a multicenter randomized controlled trial
Hardin, DS; Adams-Huet, B; Brown, D; Chatfield, B; Dyson, M; Ferkol, T; Howenstine, M; Prestidge, C; Royce, F; Rice, J; Seilheimer, DK; Steelman, J; Shepherds, R
Journal of Clinical Endocrinology & Metabolism, 91(): 4925-4929.
10.1210/jc.2006-1101
CrossRef
Clinical Chemistry
Potential utility of plasma fatty acid analysis the diagnosis of cystic fibrosis
Batal, I; Ericsoussi, MB; Cluette-Brown, JE; O'Sullivan, BP; Freedman, SD; Savaille, JE; Laposata, M
Clinical Chemistry, 53(1): 78-84.
10.1373/clinchem.2006.077008
CrossRef
Journal of Cystic Fibrosis
Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis
Maqbool, A; Graham-Maar, RC; Schall, JI; Zemel, BS; Stallings, VA
Journal of Cystic Fibrosis, 7(2): 137-141.
10.1016/j.jcf.2007.07.002
CrossRef
Journal of Cystic Fibrosis
Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis
Hirche, TO; Hirche, H; Jungblut, S; Stern, M; Wagner, TO; Wiedemann, B
Journal of Cystic Fibrosis, 8(4): 238-244.
10.1016/j.jcf.2009.03.004
CrossRef
Journal of Cystic Fibrosis
Evaluation of salt supplementation in CF infants
Coates, AJ; Crofton, PM; Marshall, T
Journal of Cystic Fibrosis, 8(6): 382-385.
10.1016/j.jcf.2009.08.006
CrossRef
Plos One
CFTR Depletion Results in Changes in Fatty Acid Composition and Promotes Lipogenesis in Intestinal Caco 2/15 Cells
Mailhot, G; Rabasa-Lhoret, R; Moreau, A; Berthiaume, Y; Levy, E
Plos One, 5(5): -.
ARTN e10446
CrossRef
American Journal of Clinical Nutrition
Short-term protein intake and stimulation of protein synthesis in stunted children with cystic fibrosis
Geukers, VGM; Oudshoorn, JH; Taminiau, JAJM; van der Ent, CK; Schilte, P; Ruiter, AFC; Ackermans, MT; Endert, E; Jonkers-Schuitema, CF; Heymans, HSA; Sauerwein, HP
American Journal of Clinical Nutrition, 81(3): 605-610.

Journal of Pediatrics
Growth failure in cystic fibrosis: A true need for anabolic agents?
Colombo, C; Battezzati, A
Journal of Pediatrics, 146(3): 303-305.
10.1016/j.jpeds.2004.11.026
CrossRef
European Journal of Clinical Nutrition
Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis
Wiedemann, B; Paul, KD; Stern, M; Wagner, TO; Hirche, TO
European Journal of Clinical Nutrition, 61(6): 759-768.
10.1038/sj.ejcn.1602582
CrossRef
European Respiratory Journal
Plasma fatty acids and lipid hydroperoxides increase after antibiotic therapy in cystic fibrosis
Durieu, I; Abbas-Chorfa, F; Drai, J; Iwaz, J; Steghens, JP; Puget, M; Ecochard, R; Belllon, G
European Respiratory Journal, 29(5): 958-964.
10.1183/09031936.00000906
CrossRef
Journal of Cystic Fibrosis
Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis
Drury, D; Grey, VL; Ferland, G; Gundberg, C; Lands, LC
Journal of Cystic Fibrosis, 7(5): 457-459.
10.1016/j.jcf.2008.04.001
CrossRef
Seminars in Respiratory and Critical Care Medicine
Nutrition in Cystic Fibrosis
Matel, JL; Milla, CE
Seminars in Respiratory and Critical Care Medicine, 30(5): 579-586.
10.1055/s-0029-1238916
CrossRef
Journal of Cystic Fibrosis
Efficacy and safety of Creon (R) 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
Trapnell, BC; Maguiness, K; Graff, GR; Boyd, D; Beckmann, K; Caras, S
Journal of Cystic Fibrosis, 8(6): 370-377.
10.1016/j.jcf.2009.08.008
CrossRef
Journal of Cystic Fibrosis
EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency
Wooldridge, JL; Heubi, JE; Amaro-Galvez, R; Boas, SR; Blake, KV; Nasr, SZ; Chatfield, B; McColley, SA; Woo, MS; Hardy, KA; Kravitz, RM; Strafonini, C; Anelli, M; Lee, C
Journal of Cystic Fibrosis, 8(6): 405-417.
10.1016/j.jcf.2009.07.006
CrossRef
Journal of Cystic Fibrosis
An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth
Salvatore, D; Buzzetti, R; Baldo, E; Forneris, MP; Lucidi, V; Manunza, D; Marinelli, I; Messore, B; Neri, AS; Raia, V; Furnari, ML; Mastella, G
Journal of Cystic Fibrosis, 9(2): 75-83.
10.1016/j.jcf.2009.11.002
CrossRef
Childrens Health Care
A randomized pilot study of behavioral treatment to increase calorie intake in toddlers with cystic fibrosis
Powers, SW; Byars, KC; Mitchell, MJ; Patton, SR; Schindler, T; Zeller, MH
Childrens Health Care, 32(4): 297-311.

Pediatrics
Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover
Conway, SP; Wolfe, SP; Brownlee, KG; White, H; Oldroyd, B; Truscott, JG; Harvey, JM; Shearer, MJ
Pediatrics, 115(5): 1325-1331.
10.1542/peds.2004-1242
CrossRef
Pediatric Pulmonology
Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis
Homnick, DN; Marks, JH; Hare, KL; Bonnema, SK
Pediatric Pulmonology, 40(3): 251-256.
10.1002/ppul.20265
CrossRef
American Journal of Clinical Nutrition
Classification of malnutrition in cystic fibrosis: implications for evaluating and benchmarking clinical practice performance
Lai, HCJ; Shoff, SM
American Journal of Clinical Nutrition, 88(1): 161-166.

Journal of Pediatrics
Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition
Hardin, DS; Rice, J; Ahn, C; Ferkol, T; Howenstine, M; Spears, S; Prestidge, C; Seilheimer, DK; Shepherd, R
Journal of Pediatrics, 146(3): 324-328.
10.1016/j.jpeds.2004.10.037
CrossRef
Pediatrics
Randomized clinical trial of behavioral and nutrition treatment to improve energy intake and growth in toddlers and preschoolers with cystic fibrosis
Powers, SW; Jones, JS; Ferguson, KS; Piazza-Waggoner, C; Daines, C; Acton, JD
Pediatrics, 116(6): 1442-1450.
10.1542/peds.2004-2823
CrossRef
Pediatric Pulmonology
We do not need to use gastrostomy tubes (GT) to improve outcomes in patients with CF
Powers, SW; Sullivan, SM; Crawford, MJ
Pediatric Pulmonology, (): 115-117.

Pediatric Diabetes
Management of cystic fibrosis-related diabetes
O'Riordan, SMP; Robinson, PD; Donaghue, KC; Moran, A
Pediatric Diabetes, 9(4): 338-344.
10.1111/j.1399-5448.2008.00437.x
CrossRef
Journal of Pediatric Health Care
Improving nutrition in the cystic fibrosis patient
Pitts, J; Flack, J; Goodfellow, J
Journal of Pediatric Health Care, 22(2): 137-140.
10.1016/j.pedhc.2007.12.011
CrossRef
Journal of Pediatrics
Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis
Borowitz, D; Robinson, KA; Rosenfeld, M; Davis, SD; Sabadosa, KA; Spear, SL; Michel, SH; Parad, RB; White, TB; Farrell, PM; Marshall, BC; Accurso, FJ
Journal of Pediatrics, 155(6): S73-S93.
10.1016/j.jpeds.2009.09.001
CrossRef
Hormone Research
Cystic Fibrosis-Related Diabetes in Childhood
O'Riordan, SMP; Dattani, MT; Hindmarsh, PC
Hormone Research, 73(1): 15-24.
10.1159/000271912
CrossRef
Archives De Pediatrie
Influence of nutritional status on the evolution of cystic fibrosis: Clinical and epidemiological aspects
Mouterde, O
Archives De Pediatrie, 10(): 421S-430S.

Journal of Cystic Fibrosis
Incorporating genetic potential when evaluating stature in children with cystic fibrosis
Zhang, ZM; Shoff, SM; Lai, HJC
Journal of Cystic Fibrosis, 9(2): 135-142.
10.1016/j.jcf.2010.01.003
CrossRef
Zdravniski Vestnik-Slovenian Medical Journal
Guidelines for Management of Children With Cystic Fibrosis
Beden, AB; Brecelj, J; Bratanic, N; Homan, M; Homsak, M; Jenko, K; Kenig, A; Ostir, M; Skocir, L; Campa, AS
Zdravniski Vestnik-Slovenian Medical Journal, 77(): 679-692.

Journal of the American Dietetic Association
Validating Dietary Intake with Biochemical Markers
Hardin, DS
Journal of the American Dietetic Association, 109(): 1698-1699.
10.1016/j.jada.2009.07.014
CrossRef
American Journal of Physiology-Gastrointestinal and Liver Physiology
CFTR knockdown stimulates lipid synthesis and transport in intestinal Caco-2/15 cells
Mailhot, G; Ravid, Z; Barchi, S; Moreau, A; Rabasa-Lhoret, R; Levy, E
American Journal of Physiology-Gastrointestinal and Liver Physiology, 297(6): G1239-G1249.
10.1152/ajpgi.00206.2009
CrossRef
Pediatric Clinics of North America
Nutrition Management of Pediatric Patients Who Have Cystic Fibrosis
Michel, SH; Maqbool, A; Hanna, MD; Mascarenhas, M
Pediatric Clinics of North America, 56(5): 1123-+.
10.1016/j.pcl.2009.06.008
CrossRef
Archives De Pediatrie
How and when to evaluate the nutritional status of children with cystic fibrosis
Tounian, P
Archives De Pediatrie, 10(): 431S-436S.

Acta Paediatrica
Benefits of breastfeeding in cystic fibrosis: A single-centre follow-up survey
Colombo, C; Costantini, D; Zazzeron, L; Faelli, N; Russo, MC; Ghisleni, D; Gatelli, I; Giovannini, M; Riva, E; Zetterstrom, R; Agostoni, C
Acta Paediatrica, 96(8): 1228-1232.
10.1111/j.1651-2227.2007.00397.x
CrossRef
New England Journal of Medicine
Association of cystic fibrosis with abnormalities in fatty acid metabolism
Freedman, SD; Blanco, PG; Zaman, MM; Shea, JC; Ollero, M; Hopper, IK; Weed, DA; Gelrud, A; Regan, MM; Laposata, M; Alvarez, JG; O'Sullivan, BP
New England Journal of Medicine, 350(6): 560-569.

Clinical Endocrinology
A retrospective study of growth hormone use in adolescents with cystic fibrosis
Hardin, DS; Ferkol, T; Ahn, C; Dreimane, D; Dyson, M; Morse, M; Prestidge, C; Rice, J; Seilheimer, DK
Clinical Endocrinology, 62(5): 560-566.
10.1111/j.1365-2265.2005.02259.x
CrossRef
Journal of Pediatric Endocrinology & Metabolism
Growth hormone improves bone mineral content in children with cystic fibrosis
Hardin, DS; Ahn, C; Prestidge, C; Seilheimer, DK; Ellis, KJ
Journal of Pediatric Endocrinology & Metabolism, 18(6): 589-595.

British Journal of Nutrition
The nutritional status of children with cystic fibrosis
Murphy, AJ; Buntain, HM; Wainwright, CE; Davies, PSW
British Journal of Nutrition, 95(2): 321-324.
10.1079/BJN20051611
CrossRef
Journal of the American Dietetic Association
Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: Results of a systematic review
Stallings, VA; Stark, LJ; Robinson, KA; Feranchak, AP; Quinton, H
Journal of the American Dietetic Association, 108(5): 832-839.
10.1016/j.jada.2008.02.020
CrossRef
Nutricion Hospitalaria
Nutrition, cystic fibrosis and the digestive tract
Olveira, G; Olveira, C
Nutricion Hospitalaria, 23(): 71-86.

Childrens Health Care
A tool to individualize nutritional care for children with cystic fibrosis: Reliability, validity, and utility of the CF individualized NuTritional Assessment of Kids Eating (CF INTAKE)
Powers, SW; Patton, SR; Henry, R; Heidemann, M; Stark, LJ
Childrens Health Care, 34(2): 113-131.

Journal of Cystic Fibrosis
Unresponsive or non-compliant steatorrhea in cystic fibrosis?
Lisowska, A; Kaminska, B; Grzymislawski, M; Herzig, KH; Walkowiak, J
Journal of Cystic Fibrosis, 5(4): 253-255.
10.1016/j.jcf.2006.05.006
CrossRef
Journal of Cystic Fibrosis
Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis
Padman, R; Werk, LN; Ramirez-Garnica, G; Ye, G; Nathanson, I
Journal of Cystic Fibrosis, 7(5): 385-390.
10.1016/j.jcf.2008.01.005
CrossRef
Clinical Genetics
Non-classic cystic fibrosis associated with D1152H CFTR mutation
Burgel, PR; Fajac, I; Hubert, D; Grenet, D; Stremler, N; Roussey, M; Siret, D; Languepin, J; Mely, L; Fanton, A; Labbe, A; Domblides, P; Vic, P; Dagorne, M; Reynaud-Gaubert, M; Counil, F; Varaigne, F; Bienvenu, T; Bellis, G; Dusser, D
Clinical Genetics, 77(4): 355-364.
10.1111/j.1399-0004.2009.01294.x
CrossRef
Archives De Pediatrie
Influence of nutritional status on the evolution of cystic fibrosis: Physiopathological, epidemiological and clinical aspects of nutritional disorders
Roullet-Renoleau, N
Archives De Pediatrie, 10(): 449S-452S.

Childrens Health Care
A comparison using parent report and direct observation of mealtime behaviors in young children with cystic fibrosis: Implications for practical and empirically based behavioral assessment in routine clinical care
Piazza-Waggoner, C; Driscoll, KA; Gilman, DK; Powers, SW
Childrens Health Care, 37(1): 38-48.
10.1080/02739610701766875
CrossRef
Pediatric Pulmonology
Improved pulmonary and growth outcomes in cystic fibrosis by newborn screening
Melanie, S; Abbott, MA; Wakefield, DB; Lapin, CD; Drapeau, G; Hopfer, SM; Greenstein, RM; Cloutier, MM
Pediatric Pulmonology, 43(7): 648-655.
10.1002/ppul.20842
CrossRef
Journal of Cystic Fibrosis
Undercarboxylated osteocalcin and bone mass in 8-12 year old children with cystic fibrosis
Fewtrell, MS; Benden, C; Williams, JE; Chomtho, S; Ginty, F; Nigdikar, SV; Jaffe, A
Journal of Cystic Fibrosis, 7(4): 307-312.
10.1016/j.jcf.2007.11.006
CrossRef
Journal of Cystic Fibrosis
Use of the insulin pump in treat cystic fibrosis related diabetes
Hardin, DS; Rice, J; Rice, M; Rosenblatt, R
Journal of Cystic Fibrosis, 8(3): 174-178.
10.1016/j.jcf.2008.12.001
CrossRef
Journal of Pediatric Endocrinology & Metabolism
Insulin-like Growth Factor-I Levels Predict Weight, Height and Protein Catabolism in Children and Adolescents with Cystic Fibrosis
Switzer, M; Rice, J; Rice, M; Hardin, DS
Journal of Pediatric Endocrinology & Metabolism, 22(5): 417-424.

Hormone Research in Paediatrics
Cystic Fibrosis-Related Diabetes in Childhood
O'Riordan, SMP; Dattani, MT; Hindmarsh, PC
Hormone Research in Paediatrics, 73(1): 15-24.
10.1159/000271912
CrossRef
European Journal of Pediatrics
Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes
Proesmans, M; De Boeck, K
European Journal of Pediatrics, 162(): 760-763.
10.1007/s00431-003-1309-5
CrossRef
Best Practice & Research in Clinical Gastroenterology
Cystic fibrosis: Nutritional consequences and management
Dodge, JA; Turck, D
Best Practice & Research in Clinical Gastroenterology, 20(3): 531-546.
10.1016/j.bpg.2005.11.006
CrossRef
European Journal of Endocrinology
Spontaneous hypoglycemia in patients with cystic fibrosis
Battezzati, A; Battezzati, PM; Costantini, D; Seia, M; Zazzeron, L; Russo, MC; Dacco, V; Bertoli, S; Crosignani, A; Colombo, C
European Journal of Endocrinology, 156(3): 369-376.
10.1530/eje.1.02344
CrossRef
Clinics in Chest Medicine
Current issues in quality improvement in cystic fibrosis
Quinton, HB; O'Connor, GT
Clinics in Chest Medicine, 28(2): 459-+.
10.1016/j.ccm.2007.02.013
CrossRef
Pediatric Pulmonology
We need to use gastrostomy tubes to improve outcomes in patients with CF
Erskine, J
Pediatric Pulmonology, (): 117-118.

Journal of the American Dietetic Association
A comparison of nutrient intake between infants and toddlers with and without cystic fibrosis
Powers, SW; Patton, SR
Journal of the American Dietetic Association, 103(): 1620-1625.
10.1016/S0002-8223(03)01367-1
CrossRef
Pediatric Pulmonology
Survey of breast-feeding practices and outcomes in the cystic fibrosis population
Parker, EM; O'Sullivan, BP; Shea, JC; Regan, MM; Freedman, SD
Pediatric Pulmonology, 37(4): 362-367.
10.1002/ppul.10450
CrossRef
Journal of Human Nutrition and Dietetics
A comparison of food group variety between toddlers with and without cystic fibrosis
Powers, SW; Patton, SR; Rajanj, S
Journal of Human Nutrition and Dietetics, 17(6): 523-527.

British Medical Journal
Nutritional supplements in cystic fibrosis
Kappler, M; Griese, M
British Medical Journal, 332(): 618-619.

Clinics in Chest Medicine
Nutrition and lung disease in cystic fibrosis
Milla, CE
Clinics in Chest Medicine, 28(2): 319-+.
10.1016/j.ccm.2007.02.006
CrossRef
Pediatric Pulmonology
CF quality improvement: Effect on outcomes
Schechter, MS
Pediatric Pulmonology, (): 167-168.

Jama-Journal of the American Medical Association
Adult cystic fibrosis
Boyle, MP
Jama-Journal of the American Medical Association, 298(): 1787-1793.

Childrens Health Care
The impact of behavioral intervention on family interactions at mealtime in pediatric cystic fibrosis
Janicke, DM; Mitchell, MJ; Quittner, AL; Piazza-Waggoner, C; Stark, LJ
Childrens Health Care, 37(1): 49-66.
10.1080/02739610701766891
CrossRef
Nutrition & Dietetics
Nutritional management of cystic fibrosis in Australia and New Zealand
King, SJ; Collins, CE; Crowder, T; Matson, AG; Volders, E
Nutrition & Dietetics, 65(4): 253-258.
10.1111/j.1747-0080.2008.00314.x
CrossRef
Health Psychology
Child behavior and parent management strategies at mealtimes in families with a school-age child with cystic fibrosis
Stark, LJ; Opipari, LC; Jelalian, E; Powers, SW; Janicke, DM; Mulvihill, MM; Hovell, MF
Health Psychology, 24(3): 274-280.
10.1037/0278-6133.24.3.274
CrossRef
Pediatric Pulmonology
Survey of professionals' expectations of developmental task achievement of cystic fibrosis self-care in children
Patton, SR; Graham, JL; Holsclaw, D; Varlotta, L
Pediatric Pulmonology, 40(2): 135-140.
10.1002/ppul.20262
CrossRef
American Journal of Clinical Nutrition
Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis
Trabulsi, J; Ittenbach, RF; Schall, JI; Olsen, IE; Yudkoff, M; Daikhin, Y; Zemel, BS; Stallings, VA
American Journal of Clinical Nutrition, 85(1): 144-151.

Respiratory Care
Relationship between nutritional status and maximum inspiratory and expiratory pressures in cystic fibrosis
Ziegler, B; Lukrafka, JL; Abraao, CLD; Rovedder, PM; Dalcin, PDR
Respiratory Care, 53(4): 442-449.

Journal of Pediatrics
Relation between pancreatic lipase activity and gastric emptying rate in children with cystic fibrosis
Symonds, EL; Omari, TI; Webster, JM; Davidson, GP; Butler, RN
Journal of Pediatrics, 143(6): 772-775.
10.1067/S0022-3476(03)00581-X
CrossRef
Nutrition in Clinical Practice
Update on enteral nutrition support for cystic fibrosis
Erskine, JM; Lingard, C; Sontag, M
Nutrition in Clinical Practice, 22(2): 223-232.

Nefrologia
Risk of urolithiasis in patients with Cystic Fibrosis
Campuzano, S; Diaz, JJ; Bousono, C; Rodriguez, M; Campos, C; Malaga, S
Nefrologia, 29(1): 61-66.

Lancet
Cystic fibrosis
O'Sullivan, BP; Freedman, SD
Lancet, 373(): 1891-1904.
10.1016/S0140-6736(09)60327-5
CrossRef
Jornal Brasileiro De Pneumologia
Association between nutritional status measurements and pulmonary function in children and adolescents with cystic fibrosis
Chaves, CRMD; de Britto, JAA; de Oliveira, CQ; Gomes, MM; da Cunha, ALP
Jornal Brasileiro De Pneumologia, 35(5): 409-414.

Clinical Therapeutics
Efficacy and Tolerability of a New Formulation of Pancrelipase Delayed-Release Capsules in Children Aged 7 to 11 Years With Exocrine Pancreatic Insufficiency and Cystic Fibrosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Superiority Study
Graff, GR; Maguiness, K; McNamara, J; Morton, R; Boyd, D; Beckmann, K; Bennett, D
Clinical Therapeutics, 32(1): 89-103.
10.1016/j.clinthera.2010.01.012
CrossRef
Jornal Brasileiro De Pneumologia
Nutritional, clinical and socioeconomic profile of patients with cystic fibrosis treated at a referral center in northeastern Brazil
Pinto, ICD; da Silva, CP; de Britto, MCA
Jornal Brasileiro De Pneumologia, 35(2): 137-143.

Archives De Pediatrie
Physiopathological aspects of nutritional disorders in cystic fibrosis
Turck, D
Archives De Pediatrie, 10(): 413S-420S.

American Journal of Clinical Nutrition
Comparison of the use of body mass index percentiles and percentage of ideal body weight to screen for malnutrition in children with cystic fibrosis
Zhang, ZM; Lai, HCJ
American Journal of Clinical Nutrition, 80(4): 982-991.

Pediatrics
Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fibrosis
Shoff, SM; Ahn, HY; Davis, L; Lai, HC
Pediatrics, 117(2): 391-400.
10.1542/peds.2004-2832
CrossRef
Pediatric Pulmonology
Cystic fibrosis mutations with widely variable phenotype: The D1152H example
Mussaffi, H; Prais, D; Mei-Zahav, M; Blau, H
Pediatric Pulmonology, 41(3): 250-254.
10.1002/ppul.20343
CrossRef
Journal of Pediatric Psychology
Examining clinical trial results with single-subject analysis: An example involving behavioral and nutrition treatment for young children with cystic fibrosis
Powers, SW; Piazza-Waggoner, C; Jones, JS; Ferguson, KS; Daines, C; Acton, JD
Journal of Pediatric Psychology, 31(6): 574-581.
10.1093/jpepsy/jsj049
CrossRef
Pediatric Pulmonology
Case study: Providing evidence-based behavioral and nutrition treatment to a toddler with cystic fibrosis and multiple food allergies via telehealth
Piazza-Waggoner, C; Ferguson, KS; Daines, C; Acton, JD; Powers, SW
Pediatric Pulmonology, 41(): 1001-1004.
10.1002/ppul.20470
CrossRef
Pediatrics International
Protein-energy malnutrition as the first manifestation of cystic fibrosis in infancy
Fustik, S; Jacovska, T; Spirevska, L; Koceva, S
Pediatrics International, 51(5): 678-683.
10.1111/j.1442-200X.2009.02855.x
CrossRef
Journal of the American Dietetic Association
An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: A prospective, randomized study
Brady, MS; Garson, JL; Krug, SK; Kaul, A; Rickard, KA; Caffrey, HH; Fineberg, N; Balistreri, WF; Stevens, JC
Journal of the American Dietetic Association, 106(8): 1181-1186.
10.1016/j.jada.2006.05.011
CrossRef
Hormone Research
Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis
Boguszewski, MCS; Kamoi, TO; Radominski, RB; Boguszewski, CL; Rosberg, S; Rosario, NA; Neto, RS; Albertsson-Wikland, K
Hormone Research, 67(5): 250-256.
10.1159/000098480
CrossRef
Pediatric Research
Persistence of Essential Fatty Acid Deficiency in Cystic Fibrosis Despite Nutritional Therapy
Aldamiz-Echevarria, L; Prieto, J; Andrade, F; Elorz, J; Sojo, A; Lage, S; Sanjurjo, P; Vazquez, C; Rodriguez-Soriano, J
Pediatric Research, 66(5): 585-589.

Behavior Therapy
Contribution of behavior therapy to dietary treatment in cystic fibrosis: A randomized controlled study with 2-year follow-up
Stark, LJ; Opipari, LC; Spieth, LE; Jelalian, E; Quittner, AL; Higgins, L; Mackner, L; Byars, K; Lapey, A; Stallings, VA; Duggan, C
Behavior Therapy, 34(2): 237-258.

Pediatric Pulmonology
Cyproheptadine is an effective appetite stimulant in cystic fibrosis
Homnick, DN; Homnick, BD; Reeves, AJ; Marks, JH; Pimentel, RS; Bonnema, SK
Pediatric Pulmonology, 38(2): 129-134.
10.1002/ppul.20043
CrossRef
Archives of Disease in Childhood
Weight and energy: parents' and children's perspectives on managing cystic fibrosis diet
Savage, E; Callery, P
Archives of Disease in Childhood, 90(3): 249-252.
10.1136/adc.2004.056804
CrossRef
Journal of Pediatrics
Improving subspecialty healthcare: Lessons from cystic fibrosis
Schechter, MS; Margolis, P
Journal of Pediatrics, 147(3): 295-301.
10.1016/j.jpeds.2005.03.044
CrossRef
Clinical Nutrition
Adolescent development and energy expenditure in females with cystic fibrosis
Stallings, VA; Tomezsko, JL; Schall, JI; Mascarenhas, MR; Stettler, N; Scanlin, TF; Zemel, BS
Clinical Nutrition, 24(5): 737-745.
10.1016/j.clnu.2005.02.005
CrossRef
Pediatric Pulmonology
Percent true calcium absorption, mineral metabolism, and bone mineralization in children with cystic fibrosis: Effect of supplementation with vitamin D and calcium
Hillman, LS; Cassidy, JT; Popescu, MF; Hewett, JE; Kyger, J; Robertson, D
Pediatric Pulmonology, 43(8): 772-780.
10.1002/ppul.20863
CrossRef
Pediatrics
Prevalence of Low Bone Mass and Deficiencies of Vitamins D and K in Pediatric Patients With Cystic Fibrosis From 3 Canadian Centers
Grey, V; Atkinson, S; Drury, D; Casey, L; Ferland, G; Gundberg, C; Lands, LC
Pediatrics, 122(5): 1014-1020.
10.1542/peds.2007-2336
CrossRef
Journal of Pediatrics
Better Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with Cystic Fibrosis
Yen, EH; Quinton, H; Borowitz, D
Journal of Pediatrics, 162(3): 530-+.
10.1016/j.jpeds.2012.08.040
CrossRef
Journal of the Academy of Nutrition and Dietetics
Nutrition for Pregnant Women Who Have Cystic Fibrosis
Michel, SH; Mueller, DH
Journal of the Academy of Nutrition and Dietetics, 112(): 1943-1948.
10.1016/j.jand.2012.08.010
CrossRef
American Journal of Clinical Nutrition
Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study
Stephenson, AL; Mannik, LA; Walsh, S; Brotherwood, M; Robert, R; Darling, PB; Nisenbaum, R; Moerman, J; Stanojevic, S
American Journal of Clinical Nutrition, 97(4): 872-877.
10.3945/ajcn.112.051409
CrossRef
Nutrition in Clinical Practice
A Survey of Nutrition Practices for Patients With Cystic Fibrosis
O'Brien, CE; Harden, H; Com, G
Nutrition in Clinical Practice, 28(2): 237-241.
10.1177/0884533612466113
CrossRef
Drugs
Ivacaftor: A Review of Its Use in Patients with Cystic Fibrosis
Deeks, ED
Drugs, 73(): 1595-1604.
10.1007/s40265-013-0115-2
CrossRef
Clinical Pharmacology & Therapeutics
Longitudinal Cystic Fibrosis Care
Antunovic, SS; Lukac, M; Vujovic, D
Clinical Pharmacology & Therapeutics, 93(1): 86-97.
10.1038/clpt.2012.183
CrossRef
Journal of Pediatrics
Pubertal Height Velocity and Associations with Prepubertal and Adult Heights in Cystic Fibrosis
Zhang, ZM; Lindstrom, MJ; Lai, HCJ
Journal of Pediatrics, 163(2): 376-+.
10.1016/j.jpeds.2013.02.026
CrossRef
International Journal of Clinical Pharmacology and Therapeutics
Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis
Stallings, VA; Mondick, JT; Schall, JI; Barrett, JS; Wilson, M; Mascarenhas, MR
International Journal of Clinical Pharmacology and Therapeutics, 51(4): 263-273.
10.5414/CP201793
CrossRef
Lipids
Interactions of Linoleic and Alpha-Linolenic Acids in the Development of Fatty Acid Alterations in Cystic Fibrosis
Katrangi, W; Lawrenz, J; Seegmiller, AC; Laposata, M
Lipids, 48(4): 333-342.
10.1007/s11745-013-3768-4
CrossRef
Clinical Nutrition
Stunting is an independent predictor of mortality in patients with cystic fibrosis
Vieni, G; Faraci, S; Collura, M; Lombardo, M; Traverso, G; Cristadoro, S; Termini, L; Lucanto, MC; Furnari, ML; Trimarchi, G; Triglia, MR; Costa, S; Pellegrino, S; Magazzu, G
Clinical Nutrition, 32(3): 382-385.
10.1016/j.clnu.2012.08.017
CrossRef
Current Opinion in Pediatrics
Improving the quality of care for patients with cystic fibrosis
Schechter, MS; Gutierrez, HH
Current Opinion in Pediatrics, 22(3): 296-301.
10.1097/MOP.0b013e328339550e
PDF (183) | CrossRef
Current Opinion in Pulmonary Medicine
Classification of nutritional status in cystic fibrosis
Lai, HJ
Current Opinion in Pulmonary Medicine, 12(6): 422-427.
10.1097/01.mcp.0000245709.66762.f9
PDF (98) | CrossRef
Current Opinion in Pulmonary Medicine
Update on fat-soluble vitamins in cystic fibrosis
Maqbool, A; Stallings, VA
Current Opinion in Pulmonary Medicine, 14(6): 574-581.
10.1097/MCP.0b013e3283136787
PDF (140) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Assessment of Phospholipid Malabsorption by Quantification of Fecal Phospholipid
Chen, A; Innis, S
Journal of Pediatric Gastroenterology and Nutrition, 39(1): 85-91.

PDF (328)
Journal of Pediatric Gastroenterology and Nutrition
Meal Patterns, Dietary Fat Intake and Pancreatic Enzyme Use in Preadolescent Children With Cystic Fibrosis
Schall, JI; Bentley, T; Stallings, VA
Journal of Pediatric Gastroenterology and Nutrition, 43(5): 651-659.
10.1097/01.mpg.0000234082.47884.d9
PDF (156) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Dietary and Circulating Polyunsaturated Fatty Acids in Cystic Fibrosis: Are They Related to Clinical Outcomes?
Colombo, C; Bennato, V; Costantini, D; Valmarana, L; Daccò, V; Zazzeron, L; Ghisleni, D; Bruzzese, MG; Scaglioni, S; Riva, E; Agostoni, C
Journal of Pediatric Gastroenterology and Nutrition, 43(5): 660-665.
10.1097/01.mpg.0000235978.59873.04
PDF (128) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Growth Assessment of Paediatric Patients With CF Comparing Different Auxologic Indicators: A Multicentre Italian Study
Maglieri, M; Guidotti, ML; Ravaioli, E; Pesola, M; De Alessandri, A; Padoan, R; Grynzich, L; Ratclif, L; Repetto, T; Ambroni, M; Provenzano, E; Tozzi, AE; Colombo, C; Lucidi, V; Alghisi, F; Raia, V; Russo, B; Valmarana, L; Valmarana, R; Coruzzo, A; Beschi, S; Dester, S; Rinaldi, D
Journal of Pediatric Gastroenterology and Nutrition, 49(3): 335-342.
10.1097/MPG.0b013e31818f0a39
PDF (1668) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Acetate Correction for Postabsorption Metabolism Does Not Improve the [13C]Mixed Triacylglycerol Breath Test
Slater, C; Preston, T; Weaver, LT
Journal of Pediatric Gastroenterology and Nutrition, 43(5): 666-672.
10.1097/01.mpg.0000232569.66699.93
PDF (173) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Serum Linoleic Acid Status as a Clinical Indicator of Essential Fatty Acid Status in Children With Cystic Fibrosis
Maqbool, A; Schall, JI; Garcia-Espana, JF; Zemel, BS; Strandvik, B; Stallings, VA
Journal of Pediatric Gastroenterology and Nutrition, 47(5): 635-644.
10.1097/MPG.0b013e31817fb76b
PDF (161) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Plasma Zinc and Growth Status in Preadolescent Children with Cystic Fibrosis
Maqbool, A; Schall, JI; Zemel, BS; Garcia-Espana, J; Stallings, VA
Journal of Pediatric Gastroenterology and Nutrition, 43(1): 95-101.
10.1097/01.mpg.0000228093.36089.35
PDF (132) | CrossRef
Journal of Pediatric Gastroenterology and Nutrition
Validation of a Nutrition Risk Screening Tool for Children and Adolescents With Cystic Fibrosis Ages 2–20 Years
McDonald, CM
Journal of Pediatric Gastroenterology and Nutrition, 46(4): 438-446.
10.1097/MPG.0b013e318156c2db
PDF (330) | CrossRef
Journal of Developmental & Behavioral Pediatrics
Family Functioning in Young Children with Cystic Fibrosis: Observations of Interactions at Mealtime
MITCHELL, MJ; POWERS, SW; BYARS, KC; DICKSTEIN, S; STARK, LJ
Journal of Developmental & Behavioral Pediatrics, 25(5): 335-346.

PDF (1259)
Pancreas
Efficacy and Tolerability of Creon for Children in Infants and Toddlers With Pancreatic Exocrine Insufficiency Caused by Cystic Fibrosis: An Open-Label, Single-Arm, Multicenter Study
Colombo, C; Fredella, C; Russo, MC; Faelli, N; Motta, V; Valmarana, L; Longo, L; D'Orazio, C
Pancreas, 38(6): 693-699.
10.1097/MPA.0b013e3181a85eaf
PDF (163) | CrossRef
Back to Top | Article Outline

© 2002 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Images

Share

Connect With Us

 

 

Twitter

twitter.com/JPGNonline

 

Visit JPGN.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.